Development and Validation of a Novel Fibrosis Marker in Biliary Atresia during Infancy

Area of Science:

• Pediatric Surgery
• Hepatology
• Biomarker Development

Background:

• Biliary atresia (BA) frequently leads to liver fibrosis and necessitates liver transplantation in affected infants.
• Accurate, noninvasive assessment of liver fibrosis is crucial for managing BA patients under one year of age.
• Previous fibrosis markers were not specifically validated for this young pediatric population.

Purpose of the Study:

• To develop and validate a novel, noninvasive scoring system, the infant BA liver fibrosis (iBALF) score.
• To assess the iBALF score's accuracy in determining native liver fibrosis stages in BA patients younger than one year.
• To evaluate the iBALF score's predictive value for native liver survival in this cohort.

Main Methods:

• Retrospective analysis of BA patients (<1 year) from three pediatric surgery institutions.
• Development and validation cohorts were established based on institutional data.
• Multivariate logistic regression analysis was used to derive the iBALF score using serum total bilirubin, platelet count, and age; correlation with histological fibrosis stages (F0-F4) was assessed.

Main Results:

• The iBALF score, incorporating serum total bilirubin, platelet count, and age, showed strong correlations with fibrosis stages (r=0.80 and 0.73).
• High diagnostic accuracy for fibrosis stages was confirmed by ROC curve analysis (AUCs 0.86-0.94 and 0.86-0.90).
• An iBALF score >6 (indicating advanced fibrosis) predicted 1-year native liver non-survival.

Conclusions:

• The developed iBALF score is a reliable noninvasive marker for assessing native liver fibrosis in infants with biliary atresia.
• The iBALF score demonstrates significant diagnostic power for various fibrosis stages in this pediatric population.
• This novel score aids in clinical decision-making for managing BA patients.